Lupin ties up with Amman Pharma for commercialisation of biosimilar productLupin has inked a licensing pact for the commercialisation and marketing of Ranibizumab, a biosimilar of Lucentis, in various countries inc...
Alkem Laboratories Q2 Results: Net profit up 77% YoY at Rs 615 croreTotal expenses in the quarter were marginally higher at Rs 2,797.66 crore, as against Rs 2,727.71 crore in the same period a year ago, the ...
Lupin's JV completes global trials for RA biosimilarThe randomised trial of 52 weeks was conducted in 11 countries and included over 500 patients, Lupin said.
Indian drug regulator backs off over use of Roche’s AvastinThe Drug Controller General of India has passed an order removing an alert notice for the use of Roche’s Avastin (bevacizumab) injection to...
Make in India: Can India be a hub for the $200 billion worth biosimilars opportunityThe Indian biogenerics industry is poised to exploit the opportunity they did in the case of generics, although it has no clear advantage a...
How Dr Reddy’s is rebooting its biosimilars playDr Reddy’s was among the first to race off the blocks with four launches in India about as many years. But things have slowed since.
Intas Pharmaceuticals to launch its first biosimilar in US in 9-12 monthsIntas is the only domestic firm with two biosimilars filed for registration in the US and it looks to deliver affordable and innovative pha...
New way of preventing diabetes-associated blindness foundScientists have found a new way of preventing a blinding eye disease caused due to diabetes,by blocking a second blood vessel growth protein